focus -WSS

focus

author：focus 2025-08-29 19:41:18 - browse：9563

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Unmasking the 'centricity' illusion in clinical trials

hotspot

leisure time

WSS

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Bird flu makes raw milk dangerous to consume, mouse study finds

White House drug shortage group privately met with industry

TytoCare raises $49 million to build out AI

What the cancer research community can learn from the Covid response

leisure time

focus

A Worst CEO gets some much-needed help

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Beyond aggravation: Constipation is an American epidemic

Continuity nursing helped my family in our darkest PICU moments

ProMED, early warning system on disease outbreaks, in peril

In age of alternative facts, a scholarly course on calling out crap

Gilgo Beach: Police identify another victim in serial killing investigation

Trump demands the U.S. pay no more for drugs than other countries … again

Some medical students still think black patients feel less pain

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The Bio Revolution is changing business and society

explore

ProMED, early warning system on disease outbreaks, in peril

The drug industry sees a key ally in the Senate prevail

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Clinicians often fail to acknowledge the pain caused by long Covid

Humana, CVS hope to turn members into patients at clinics

Some medical students still think black patients feel less pain

hotspot

knowledge

leisure time

explore